MediWound (MDWD) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. WDAY
2. AAPL
3. JNJ
4. AMAT
5. META
6. NVDA
7. NRIX
8. SPY
9. OIG
10. BAC

Go back to MediWound (MDWD) Reports In-Line Q4 EPS

MediWound Reports Fourth Quarter and Full Year 2021 Financial Results

March 17, 2022 7:00 AM EDT

Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46%

Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022

Raised Gross Proceeds of $10 Million through Public Equity Offering

Conference Call Begins Today at 8:30 am ET

YAVNE, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the Company), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a corporate update.

... More